PharmMD Launches Adhere™ Platform for Guaranteed Value-Based Care Outcomes
PharmMD, a leading medication adherence healthcare technology company, has launched Adhere™, its medication-focused platform of integrated technology solutions that uses advanced analytics to stratify consumer populations, prioritize interventions and resolve gaps in care to achieve value-based care outcomes. Adhere directs performance-based alignment between PharmMD and its clients and enables risk sharing as part of a unique guarantee that each consumer measurement conversion fee will deliver ROI.
For more than a decade, PharmMD has helped Medicare Advantage, managed Medicaid and Commercial plans as well as self-insured employers improve in their pay-for-performance programs, such as Star Ratings. The technology platform and nationwide licensed clinical team guarantees pay-for-performance program success.
“The solutions incorporated in the Adhere platform have had over a decade of results improving Star Ratings and other value-based care initiatives,” said Jason Rose, chief executive officer at PharmMD. “In 2019, nearly half of the Star Ratings will be weighted on medication adherence-related measures, and plans that begin these interventions now are already off to a great start for the next performance year.”
Today the Adhere platform touches more than six million consumers with the support of Stratify™, PharmMD’s analytics engine that uses machine learning and big data processing to identify medication adherence and quality care gaps that, if addressed, help achieve better value-based care outcomes. Stratify powers two fully integrated solutions: Resolve™, a comprehensive clinical decision support solution featuring medication adherence-focused intervention services, and OptimizeMTM™, a Medication Therapy Management (MTM) solution that addresses client goals and regulatory requirements.
The Adhere platform, ideal for health plans, employers and at-risk providers, also includes data-driven tools. These include Quantify™, an analytics engine for stratifying and prioritizing budgetary investment scenarios across each plan contract quality measure; QiLink™, a clinical workflow tool that directs live consumer and provider engagement; P3Link™, a clinical decision support tool that efficiently guides Comprehensive Medication Reviews (CMR) for MTM programs as well as medication reconciliation and medication synchronization services; and Discern™, a business analytics solution that provides real-time client data visualization of outcomes and program performance.
PharmMD is a technology solutions leader supporting health plans, self-insured employers and other risk-bearing entities for medication adherence insights and healthcare outcomes. PharmMD's Adhere platform now touches more than six million consumers through advanced analytics, technologies and engagement services that address the estimated $300 billion of unnecessary annual medical costs attributed to medication adherence issues. The company is headquartered in the Nashville suburb of Brentwood, Tennessee. For more information, please visitwww.pharmmd.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005166/en/